# EGLN1 (PHD2) role in tumor microenvironment: insights for therapeutic targeting

## TL;DR

This review discusses how the protein PHD2, encoded by EGLN1, influences the tumor microenvironment and how targeting it could improve cancer treatments.

## Contribution

The paper provides a comprehensive review of PHD2's role in the tumor microenvironment and its therapeutic potential.

## Key findings

- PHD2 regulates HIF-1α and affects blood vessel formation and immune cell activity in tumors.
- Reducing PHD2 activity can normalize blood vessels and improve oxygen delivery to tumors.
- Targeting PHD2 may enhance cancer treatment effectiveness and reduce metastasis.

## Abstract

The tumor microenvironment (TME) is often hypoxic. EGLN1, which encodes the oxygen sensor PHD2, plays a crucial role not only in the survival of cancer cells but also in regulating other cell types that reside in the TME. In this Review, we explore the role of this protein in some of the key components of the TME, focusing on the functions of EGLN1/PHD2 in endothelial, stromal and immune cells. So far, the activity of EGLN1/PHD2 has been characterized in different cell types, albeit with controversial outcomes in different cancer settings. This Review aims to discuss the role of EGLN1/PHD2 in the TME and the strategies targeting this protein that might be used to hit tumors.

Oxygen is crucial for the survival of organisms, but low oxygen levels, or hypoxia, can occur in both normal and disease conditions. This study explores how cells respond to hypoxia, focusing on a protein called PHD2, which helps regulate another protein, HIF-1α, involved in this response. The authors discuss how PHD2 affects cancer growth and the tumor microenvironment, which includes surrounding cells and blood vessels. Research highlights that PHD2 plays a key role in controlling blood vessel formation and immune cell activity in tumors. By studying mice and cancer models, the authors found that reducing PHD2 activity can normalize blood vessels and improve oxygen delivery to tumors. This can enhance the effectiveness of cancer treatments by improving drug delivery and reducing metastasis. Researchers conclude that targeting PHD2 could be a promising strategy for cancer therapy.

This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.